<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />




<title>Oncology estimand working group: achievements per year</title>

<script src="site_libs/header-attrs-2.11/header-attrs.js"></script>
<script src="site_libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="site_libs/bootstrap-3.3.5/css/bootstrap.min.css" rel="stylesheet" />
<script src="site_libs/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="site_libs/jqueryui-1.11.4/jquery-ui.min.js"></script>
<link href="site_libs/tocify-1.9.1/jquery.tocify.css" rel="stylesheet" />
<script src="site_libs/tocify-1.9.1/jquery.tocify.js"></script>
<script src="site_libs/navigation-1.1/tabsets.js"></script>

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>









<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark it active
  menuAnchor.tab('show');

  // if it's got a parent navbar menu mark it active as well
  menuAnchor.closest('li.dropdown').addClass('active');

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "&#xe258;";
  border: none;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->



<style type="text/css">

#TOC {
  margin: 25px 0px 20px 0px;
}
@media (max-width: 768px) {
#TOC {
  position: relative;
  width: 100%;
}
}

@media print {
.toc-content {
  /* see https://github.com/w3c/csswg-drafts/issues/4434 */
  float: right;
}
}

.toc-content {
  padding-left: 30px;
  padding-right: 40px;
}

div.main-container {
  max-width: 1200px;
}

div.tocify {
  width: 20%;
  max-width: 260px;
  max-height: 85%;
}

@media (min-width: 768px) and (max-width: 991px) {
  div.tocify {
    width: 25%;
  }
}

@media (max-width: 767px) {
  div.tocify {
    width: 100%;
    max-width: none;
  }
}

.tocify ul, .tocify li {
  line-height: 20px;
}

.tocify-subheader .tocify-item {
  font-size: 0.90em;
}

.tocify .list-group-item {
  border-radius: 0px;
}


</style>



</head>

<body>


<div class="container-fluid main-container">


<!-- setup 3col/9col grid for toc_float and main content  -->
<div class="row">
<div class="col-xs-12 col-sm-4 col-md-3">
<div id="TOC" class="tocify">
</div>
</div>

<div class="toc-content col-xs-12 col-sm-8 col-md-9">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">Oncology estimand WG</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-expanded="false">
    About
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="index.html">About</a>
    </li>
    <li>
      <a href="history.html">History</a>
    </li>
    <li>
      <a href="scope.html">Scope</a>
    </li>
    <li>
      <a href="status.html">Status</a>
    </li>
    <li>
      <a href="organization.html">Organization</a>
    </li>
    <li>
      <a href="achievements.html">Achievements per year</a>
    </li>
  </ul>
</li>
<li>
  <a href="taskforces.html">Task forces</a>
</li>
<li>
  <a href="ha.html">Health authority interactions</a>
</li>
<li>
  <a href="publications.html">Publications</a>
</li>
<li>
  <a href="events.html">Events</a>
</li>
<li>
  <a href="news.html">Newsletters</a>
</li>
<li>
  <a href="resources.html">Further resources</a>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">Oncology estimand working group:
achievements per year</h1>
<h4 class="date">Last change: 16 November, 2022</h4>

</div>


<div id="achievements-2019" class="section level1" number="1">
<h1><span class="header-section-number">1</span> Achievements 2019</h1>
<p>The WG created a platform for sharing experience and ensuring common
understanding of estimands in oncology trials across industry and
continues to grow both in terms of members and companies. The
discussions within the WG advanced in all subteams and several
manuscripts are under preparation. As planned, the initial content was
disseminated in 2019 via several statistical conferences in Europe and
US. One publication was submitted in 2019 and several submissions are
planned in 2020. The WG engaged with the Clinical community and
submitted abstracts to several Clinical conferences in collaboration
with key opinion leaders and industry clinicians, a poster was presented
at ESMO. Similarly, the collaboration with Health Authorities is ongoing
and expected to continue over several years. Furthermore, the SWG also
had some initial discussions with academia statisticians on potential
topics for collaboration in future.</p>
<p>The WG highlighted various estimand problems in Oncology and shared
the view of the SWG in many presentations at conferences in Europe and
US and in collaboration with EMA and FDA:</p>
<ul>
<li>invited talk at HTA EFSPI SIG 1-day event (Berlin, February
2019)</li>
<li>session (4 talks) at DAGStat (Munich, March 2019)</li>
<li>session (3 talks by WG members and EMA discussant) at LiDS
conference (Pittsburgh, June 2019)</li>
<li>2 talks at PSI conference (London, June 2019)</li>
<li>1 talk at DIA Annual meeting (San Diego, June 2019)</li>
<li>1 talk at ISCB conference (Leuven, July 2019)</li>
<li>session (4 talks and FDA discussant) at JSM (Denver, July 2019)</li>
<li>talk at EFSPI regulatory (Basel, September 2019)</li>
<li>session (3 talks) and invited to participate in a panel discussion
at ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop
(September 2019)</li>
<li>talk at ISOQoL conference (San Diego, October 2019)</li>
<li>Poster on estimands in adjuvant renal cell carcinoma in
collaboration with key opinion leaders and industry clinicians at ESMO
(September 2019)</li>
</ul>
</div>
<div id="achievements-2020" class="section level1" number="2">
<h1><span class="header-section-number">2</span> Achievements 2020</h1>
<p>Despite the many challenges in 2020 the SIG was able to relevantly
contribute to the implementation of the estimand addendum in drug
development in oncology and beyond. Key achievements are:</p>
<ul>
<li>The intercontinental team spirit that allowed to come up with a
rapid response to COVID-19 pandemic: a <a
href="https://oncoestimand.github.io/oncowg_webpage/talks/onco_estimand_COVID-19_slidedeck_v1.pdf">slidedeck</a>
discussing the impact of the pandemic on a trial’s estimand was
published on the webpage less than five weeks after WHO declared the
pandemic. A <a
href="https://doi.org/10.1080/19466315.2020.1785543">paper</a> followed
only a few weeks later.</li>
<li>Several <a
href="https://oncoestimand.github.io/oncowg_webpage/oncoestimand.html#publications">publications</a>
of the SIG were published this year, and several more are in their last
rounds of revision.</li>
<li>The SIG organized two webinars that brought together drug
developers, academics, and regulators to discuss topics around estimands
in oncology and beyond:
<ul>
<li><a href="http://bbs.ceb-institute.org/?p=1453">Estimands addendum is
final: Anything new for oncology?</a>: The highlight here was that
several clinical colleagues contributed as presenters and
panelists.</li>
<li><a href="http://bbs.ceb-institute.org/?p=1587">RCTs meeting causal
inference: principal stratum strategy and beyond.</a></li>
</ul></li>
<li>The SIG organized sessions and was invited to speak at virtual US
conferences (JSM, ASA-FDA workshop, Deming conference on applied
statistics). Further <a
href="https://oncoestimand.github.io/oncowg_webpage/conferences.html#webinar_of_the_basel_biometrics_section:_impact_of_covid-19_on_clinical_trials">talks</a>
were given at several occasions.</li>
<li>The SIG organized TCs with seven Health Authorities (FDA, HC,
Swissmedic, China, Japan, Taiwan, MHRA) to share its work and get input
on future directions.</li>
<li>Set up a webpage (<a
href="http://www.oncoestimand.org/">www.oncoestimand.org</a>) to foster
sharing of information and generated content such as presentations and
publications. As of today, the SIG has 54 members (20 from Europe, 29
from US, and 5 from Asia) representing 28 companies. Currently the SIG
is regrouping in task forces dedicated to eight topics that are
considered relevant to develop implementation of the addendum further in
oncology clinical trials. So expect more output in 2021!</li>
</ul>
</div>
<div id="achievements-2021" class="section level1" number="3">
<h1><span class="header-section-number">3</span> Achievements 2021</h1>
<p>The group has evolved into a global network of statisticians in
industry and regulatory agencies that continues to contribute to the
implementation of the ICH E9 addendum. Key achievements are:</p>
<ul>
<li>Several <a href="publications.html">publications</a> of the SIG
appeared this year.</li>
<li>The SIG has built a network of individuals with expertise and
credibility in the broader biostatistical and drug development
community. Testament to that is the fact that SIG members are regularly
invited to review and comment on scientific publications in the
field.</li>
<li>Invited by the <a
href="https://www.efspi.org/EFSPI/Working_Groups/EFSPI_EFPIA_EIWG.aspx">EFSPI/EFPIA
estimands implementation working group</a> the SIG organized two
webinars targeted at a broad audience of Clinicians, Investigators,
Regulatory Experts, Medical Writers, Ethics Committees, Statisticians:
<ul>
<li><a
href="events.html#01062021:_PSI_EIWG_Webinar:_Estimands_in_Oncology_-_How_and_Why">PSI
EIWG Webinars</a> (2 events, one for EU and one for US): Estimands in
Oncology - How and Why.</li>
</ul></li>
<li>The WG also organized a <a
href="events.html#28092021:_DIA_webinar:_Estimands_How_and_Why_-_A_Real_Life_Case_Study_in_Oncology">DIA
Webinar</a> with the same target audience, including FDA
discussants.</li>
<li>Our SIG is also formally represented in the <a
href="https://www.efspi.org/EFSPI/Working_Groups/EFSPI_EFPIA_EIWG.aspx">EFSPI/EFPIA
estimands implementation working group</a>.</li>
<li>The SIG organized sessions and was invited to speak at conferences
(Duke Industry Statistics Symposium, Society for clinicial trials, JSM,
ASA-FDA workshop, ISOQoL). Further <a href="events.html">talks</a> were
given at several occasions.</li>
<li>Members of the SIG were also invited to FDA OCE Project Significant
TCs to talk about application of estimands to decentralized trials and
comment on non-proportional hazards.</li>
<li>As a higlight of 2021 nine task forces were kicked off who have
started their work on new topics relevant to the implementation of the
addendum, and applying the addendum to extended areas such as, e.g.,
real-worl data. Find them all, including rosters and objectives, <a
href="taskforces.html">here</a>.</li>
<li>As of November 2021, the SIG has has 77 members (30 from Europe, 38
from US, and 9 from Asia) representing 36 companies / institutions, see
<a href="status.html">status</a>.</li>
<li>As an outlook in 2022 we plan to organize webinars reporting on the
content that the task forces have generated so far. One goal is also to
broaden our outreach and present not only at statistical but also at
clinical conferences. We also plan to get involved with our Health
Authority partners again.</li>
</ul>
</div>



</div>
</div>

</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->

<script>
$(document).ready(function ()  {

    // temporarily add toc-ignore selector to headers for the consistency with Pandoc
    $('.unlisted.unnumbered').addClass('toc-ignore')

    // move toc-ignore selectors from section div to header
    $('div.section.toc-ignore')
        .removeClass('toc-ignore')
        .children('h1,h2,h3,h4,h5').addClass('toc-ignore');

    // establish options
    var options = {
      selectors: "h1,h2,h3",
      theme: "bootstrap3",
      context: '.toc-content',
      hashGenerator: function (text) {
        return text.replace(/[.\\/?&!#<>]/g, '').replace(/\s/g, '_');
      },
      ignoreSelector: ".toc-ignore",
      scrollTo: 0
    };
    options.showAndHide = true;
    options.smoothScroll = true;

    // tocify
    var toc = $("#TOC").tocify(options).data("toc-tocify");
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
